Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 . (2022). SKIN The Journal of Cutaneous Medicine, 6(2), s2. https://doi.org/10.25251/skin.6.supp.2